Meeting Report

Updates in the Diffuse Large B-Cell Lymphoma Treatment Landscape

Ashley Ames, FNP-BC, and Diane Lee, AGPCNP-BC

From Memorial Sloan Kettering Cancer Center, New York, New York

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2022;13(3):341–344 | https://doi.org/10.6004/jadpro.2022.13.3.33 | © 2022 Harborside™


  

ABSTRACT

During JADPRO Live Virtual 2021, presenters discussed updates in the treatment of diffuse large B-cell lymphoma (DLBCL), including novel agents and chimeric antigen receptor (CAR) T-cell therapy, and how the treatment and management of patients with DLBCL has been affected by the COVID-19 pandemic.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.